Medical/Pharmaceuticals

GCCL and Medicover Integrated Clinical Services Announce Strategic Collaboration to Strengthen Multinational Clinical Trial Services

YONGIN, South Korea, Feb. 10, 2026 /PRNewswire/ -- GCCL Co., Ltd. (GCCL), a data-driven clinical trial services provider, and Medicover Integrated Clinical Services (MICS), part of Medicover, an international healthcare and diagnostic services company, have signed a Memorandum of Understanding (M...

2026-02-10 17:27 6547

WAT Medical's EmeTerm Wearable Device Demonstrates Superior Control of Moderate to Severe Postoperative Nausea and Vomiting in JAMA Surgery-Published Clinical Trial

VANCOUVER, BC, Feb. 9, 2026 /PRNewswire/ -- WAT Medical is proud to announce the publication of a landmark randomized clinical trial inJAMA Surgery, one of the world's most reputable and high-impact surgical journals. The study confirms that the EmeTerm wristband — a wearable device utilizing tr...

2026-02-10 03:08 7931

BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials

* BioDlink received a formal letter of appreciation from Chengdu Kanghong Pharmaceutical Group for its contribution to advancing KH815, the world's first dual-payload antibody–drug conjugate (ADC) to enter clinical development. * BioDlink enabled IND approval 1.5 months ahead of schedule throu...

2026-02-09 21:00 7954

Peijia Medical Submits EU MDR CE Mark Registration Application for GeminiOne® TEER System

HONG KONG, Feb. 9, 2026 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developedGeminiOne Transcatheter Edge-to-Edge Repair (TEER) System f...

2026-02-09 14:00 7414

Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology

SAN FRANCISCO and SUZHOU, China, Feb. 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2026-02-08 18:05 8739

Neurophet Secures FDA 510(k) Clearance for "Neurophet AQUA AD Plus," Marking Its Third U.S. Regulatory Milestone

* Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease imaging analysis * Advanced analysis of neuroimaging features associated with cerebral microbleeds and edema supports imaging-based clinical decision-making and accelera...

2026-02-06 22:00 13859

Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system

* Samsung Biologics' PCF system validated in line with globally established ISO and PAS standards * Validation reflects continued efforts to establish credible carbon accounting in support of net-zero goals * Validated system provides reliable, consistent carbon footprint data for clients I...

2026-02-06 21:00 12512

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico")  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment ofHalle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Z...

2026-02-06 21:00 9078

LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders

BEIJING, Feb. 6, 2026 /PRNewswire/ -- LakeShore Biopharma Co., Ltd ("LakeShore Biopharma" or the "Company") (OTCPK: LSBCF; OTCPK: LSBWF), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics fo...

2026-02-06 20:00 11605

Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia

SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...

2026-02-06 20:00 8020

Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line

BASKING RIDGE, N.J., Feb. 6, 2026 /PRNewswire/ -- Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL.  PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older, is bioequi...

2026-02-06 19:59 5062

PharmaResearch Receives U.S. FDA Clearance to Initiate Phase 1 Clinical Trial of Nano Anticancer Drug, PRD-101

SEONGNAM, South Korea, Feb. 6, 2026 /PRNewswire/ -- PharmaResearch Co., Ltd. (CEO:Jihoon Sohn) today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PRD-101, enabling the initiation of a Phase 1 clinical trial inthe United ...

2026-02-06 15:20 8256

Sky Labs Signs Exclusive Distribution Agreement with Otsuka Pharmaceutical for 'CART BP pro' in Japan

- Secures distribution agreement to launch CART BP pro in the Japanese hospital and clinic market - Leveraging proven technology with adoptions in 1,700+ medical institutions and national health insurance coverage in Korea SEOUL, South Korea, Feb. 5, 2026 /PRNewswire/ -- Sky Labs Inc. (CEO Jack ...

2026-02-06 09:00 6215

LifeZoom Introduces the Oclux Red Light Eye Mask--A Naturally Restorative, Aesthetics-Driven Solution for the Effects of Screen-Based Life

NEW YORK, Feb. 5, 2026 /PRNewswire/ -- LifeZoom, a natural-restorative brand, today launches Oclux, a red light eye mask that expands the company's red light product lineup. Positioned as a holistic solution that balances visual aesthetics, user experience, and daily rhythms, Oclux is designed to...

2026-02-05 22:12 7172

Jin Medical CEO Fireside Chat

CHANGZHOU, China, Feb. 5, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ:ZJYL) ("Jin Medical", and together with all its subsidiaries, the "Company"), a NASDAQ-listed leading provider of rehabilitation medical equipment hosted a CEO Fireside Chat onFebruary 2, 2026 where the CEO sha...

2026-02-05 21:57 8917

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. * Unlike ISM8969, Insilico's brain-penetrant NLR...

2026-02-05 21:00 8449

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters:Shanghai, China, CEO: Jason Zhu, "Henlius") announced today the conclusion of an exclusive commercialization and co-exclusive developm...

2026-02-05 19:44 8216

HanchorBio Accelerates Global Clinical Footprint with Multiple Oral and Poster Presentations in Q1 2026

Sustained execution and high-impact data across HanchorBio's next-generation immuno-oncology portfolio to be featured at ASCO-GI, AACR-IO, ESMO-TAT, ICNHO, and WOC TAIPEI and SHANGHAI and SAN FRANCISCO, Feb. 4, 2026 /PRNewswire/ -- HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechno...

2026-02-05 17:09 9648

Galaxy Brain Scientific's Technology Enables Landmark Parkinson's Study Published in Nature, Redefining Disease Mechanism

BEIJING, Feb. 5, 2026 /PRNewswire/ -- A research team led by Prof. Hesheng Liu, founder and Chief Scientific Officer of Galaxy Brain Scientific Inc., has published a study inNature that pinpoints the core functional circuit underlying Parkinson's disease (PD). The findings redefine the biological...

2026-02-05 13:00 6030

Yuyu Pharma Invests in James & Ella, Advancing Its Global Expansion Into Premium Pet Wellness

SEOUL, South Korea, Feb. 4, 2026 /PRNewswire/ -- Yuyu Pharma announced today a strategic investment in James & Ella, theUnited Kingdom's fastest-growing freeze-dried pet nutrition company. Founded by entrepreneurJames Middleton, James & Ella has rapidly established itself as the leader of the UK ...

2026-02-04 22:00 7175
1 ... 24252627282930 ... 261